Alivus Life Sciences acquires 65.01% stake in IQGEN-X Pharma
Alivus Life Sciences · Pharmaceuticals & Biotechnology
Key highlights
- Acquired 7,36,096 equity shares representing 65.01% of IQGEN-X Pharma's paid-up capital
- Acquisition initiated under Share Purchase Agreement dated August 18, 2026
- IQGEN-X Pharma Private Limited becomes a subsidiary of Alivus Life Sciences with effect from November 11, 2026
Why it's rated notable: The filing confirms closing of the share purchase and 65.01% acquisition, but states no deal value, so the level is kept at medium against the company's market value of ₹17,855 crore.
Original filing
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Indo Borax reports H1FY27 consolidated operating income up 16.0% to Rs 129.29 crore
- Manoj Agrawal Acquires 1.00 Crore Shares in Cubical Financial Services Limited
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.